Induction of Sustained Clinical Remission in Early Axial Spondyloarthritis Following Certolizumab Pegol Treatment: 48-Week Outcomes from C-OPTIMISE

Induction of Sustained Clinical Remission in Early Axial Spondyloarthritis Following Certolizumab Pegol Treatment: 48-Week Outcomes from C-OPTIMISE

Abstract Introduction Achievement of remission is a key treatment goal for patients with axial spondyloarthritis (axSpA). C-OPTIMISE assessed achievement of sustained clinical remission in patients with axSpA, including radiographic (r) and non-radiographic (nr) axSpA, during certolizumab pegol (CZP...

Full description

Bibliographic Details
Main Authors: Robert Landewé, Désirée van der Heijde, Maxime Dougados, Xenofon Baraliakos, Filip Van den Bosch, Karl Gaffney, Lars Bauer, Bengt Hoepken, Natasha de Peyrecave, Karen Thomas, Lianne S. Gensler
Format: Article
Language:English
Published: Adis, Springer Healthcare 2020-06-01
Series:Rheumatology and Therapy
Subjects:
Axial spondyloarthritis
Clinical remission
Early disease
TNF inhibitor
Online Access:https://doi.org/10.1007/s40744-020-00214-7

Internet

https://doi.org/10.1007/s40744-020-00214-7

Similar Items